Switch theme
Sign up to access all valuation multiples
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.
1994
28
LTM Revenue $0.2M
LTM EBITDA -$15.1M
$71.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Diamyd Medical has a last 12-month revenue of $0.2M and a last 12-month EBITDA of -$15.1M.
In the most recent fiscal year, Diamyd Medical achieved revenue of $13K and an EBITDA of -$14.0M.
Diamyd Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Diamyd Medical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.1M | $13K | XXX | XXX | XXX |
| Gross Profit | -$0.4M | -$0.3M | XXX | XXX | XXX |
| Gross Margin | -723% | -2375% | XXX | XXX | XXX |
| EBITDA | -$11.0M | -$14.0M | XXX | XXX | XXX |
| EBITDA Margin | -20367% | -108347% | XXX | XXX | XXX |
| Net Profit | -$10.3M | -$11.5M | XXX | XXX | XXX |
| Net Margin | -18959% | -89287% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Diamyd Medical's stock price is SEK 8 (or $1).
Diamyd Medical has current market cap of SEK 825M (or $81.9M), and EV of SEK 723M (or $71.8M).
See Diamyd Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $71.8M | $81.9M | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Diamyd Medical has market cap of $81.9M and EV of $71.8M.
Diamyd Medical's trades at 338.9x LTM EV/Revenue multiple, and -4.8x LTM EBITDA.
Analysts estimate Diamyd Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Diamyd Medical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $71.8M | XXX | XXX | XXX |
| EV/Revenue | 1722.1x | XXX | XXX | XXX |
| EV/EBITDA | -4.9x | XXX | XXX | XXX |
| P/E | -5.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDiamyd Medical's NTM/LTM revenue growth is -53%
Diamyd Medical's revenue per employee for the last fiscal year averaged $0K, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Diamyd Medical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Diamyd Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Diamyd Medical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -76% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -35214% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 27% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -35268% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 74218% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 110534% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Diamyd Medical acquired XXX companies to date.
Last acquisition by Diamyd Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Diamyd Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Diamyd Medical founded? | Diamyd Medical was founded in 1994. |
| Where is Diamyd Medical headquartered? | Diamyd Medical is headquartered in Sweden. |
| How many employees does Diamyd Medical have? | As of today, Diamyd Medical has 28 employees. |
| Who is the CEO of Diamyd Medical? | Diamyd Medical's CEO is Dr. Ulf Hannelius, PhD. |
| Is Diamyd Medical publicy listed? | Yes, Diamyd Medical is a public company listed on STO. |
| What is the stock symbol of Diamyd Medical? | Diamyd Medical trades under DMYD B ticker. |
| When did Diamyd Medical go public? | Diamyd Medical went public in 2013. |
| Who are competitors of Diamyd Medical? | Similar companies to Diamyd Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Diamyd Medical? | Diamyd Medical's current market cap is $81.9M |
| What is the current revenue of Diamyd Medical? | Diamyd Medical's last 12-month revenue is $0.2M. |
| What is the current EBITDA of Diamyd Medical? | Diamyd Medical's last 12-month EBITDA is -$15.1M. |
| What is the current EV/Revenue multiple of Diamyd Medical? | Current revenue multiple of Diamyd Medical is 338.9x. |
| What is the current EV/EBITDA multiple of Diamyd Medical? | Current EBITDA multiple of Diamyd Medical is -4.8x. |
| What is the current revenue growth of Diamyd Medical? | Diamyd Medical revenue growth between 2023 and 2024 was -76%. |
| Is Diamyd Medical profitable? | Yes, Diamyd Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
